Insider Selling: Orthofix Medical Inc (OFIX) CEO Sells 10,668 Shares of Stock

Share on StockTwits

Orthofix Medical Inc (NASDAQ:OFIX) CEO Brad Mason sold 10,668 shares of the business’s stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $53.71, for a total transaction of $572,978.28. Following the transaction, the chief executive officer now owns 165,120 shares in the company, valued at $8,868,595.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Brad Mason also recently made the following trade(s):

  • On Wednesday, April 17th, Brad Mason sold 5,949 shares of Orthofix Medical stock. The stock was sold at an average price of $52.35, for a total transaction of $311,430.15.

Shares of OFIX stock traded down $1.60 during trading hours on Friday, hitting $52.28. The company had a trading volume of 3,562 shares, compared to its average volume of 147,947. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.28 and a current ratio of 3.52. Orthofix Medical Inc has a fifty-two week low of $47.79 and a fifty-two week high of $74.44. The firm has a market cap of $1.03 billion, a P/E ratio of 26.84, a P/E/G ratio of 3.06 and a beta of 0.35.

Orthofix Medical (NASDAQ:OFIX) last issued its quarterly earnings data on Monday, May 6th. The medical device company reported $0.27 EPS for the quarter, missing the consensus estimate of $0.40 by ($0.13). Orthofix Medical had a return on equity of 10.45% and a net margin of 2.09%. The company had revenue of $109.10 million during the quarter, compared to analyst estimates of $110.59 million. During the same quarter in the prior year, the company posted $0.39 earnings per share. The business’s revenue was up .4% compared to the same quarter last year. As a group, research analysts predict that Orthofix Medical Inc will post 1.77 EPS for the current fiscal year.

Hedge funds have recently modified their holdings of the company. Prudential Financial Inc. increased its stake in Orthofix Medical by 3.5% during the 4th quarter. Prudential Financial Inc. now owns 32,952 shares of the medical device company’s stock worth $1,730,000 after buying an additional 1,118 shares during the period. First Quadrant L P CA increased its position in shares of Orthofix Medical by 145.5% in the 4th quarter. First Quadrant L P CA now owns 5,160 shares of the medical device company’s stock valued at $271,000 after purchasing an additional 3,058 shares during the last quarter. Cigna Investments Inc. New purchased a new stake in shares of Orthofix Medical in the 4th quarter valued at approximately $296,000. Victory Capital Management Inc. increased its position in shares of Orthofix Medical by 782.8% in the 4th quarter. Victory Capital Management Inc. now owns 326,063 shares of the medical device company’s stock valued at $17,115,000 after purchasing an additional 289,126 shares during the last quarter. Finally, Bessemer Group Inc. increased its position in shares of Orthofix Medical by 49.1% in the 4th quarter. Bessemer Group Inc. now owns 33,100 shares of the medical device company’s stock valued at $1,737,000 after purchasing an additional 10,900 shares during the last quarter. Hedge funds and other institutional investors own 97.17% of the company’s stock.

Several equities analysts have weighed in on the stock. BTIG Research reiterated a “neutral” rating on shares of Orthofix Medical in a report on Tuesday, February 26th. Zacks Investment Research upgraded shares of Orthofix Medical from a “hold” rating to a “strong-buy” rating and set a $73.00 price objective on the stock in a report on Tuesday, February 19th. BidaskClub upgraded shares of Orthofix Medical from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 9th. ValuEngine lowered shares of Orthofix Medical from a “buy” rating to a “hold” rating in a report on Tuesday, March 5th. Finally, TheStreet lowered shares of Orthofix Medical from a “b+” rating to a “c+” rating in a report on Thursday, May 9th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $61.50.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by Week Herald and is the sole property of of Week Herald. If you are viewing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark law. The original version of this piece of content can be viewed at https://weekherald.com/2019/05/17/insider-selling-orthofix-medical-inc-ofix-ceo-sells-10668-shares-of-stock.html.

Orthofix Medical Company Profile

Orthofix Medical Inc, a medical device company, provides musculoskeletal healing products and therapies worldwide. It operates through four segments: Bone Growth Therapies, Spinal Implants, Biologics, and Orthofix Extremities. The Bone Growth Therapies segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion and are indicated as treatment to enhance fusion success rates in cervical and lumbar spine, as well as a therapeutic treatment for non-spinal appendicular fractures.

Featured Article: Balanced Fund

Insider Buying and Selling by Quarter for Orthofix Medical (NASDAQ:OFIX)

Receive News & Ratings for Orthofix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix Medical and related companies with MarketBeat.com's FREE daily email newsletter.